HLA-F and MHC Class I Open Conformers Are Ligands for NK Cell Ig-like Receptors

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2013 Sep 11

PMID 24018270

Citations 81

Authors

Jodie P Goodridge

Aura Burian

Ni Lee

Daniel E Geraghty

Affiliations

Soon will be listed here.

Abstract

Killer Ig-like receptors (KIRs) are innate immune receptors expressed by NK and T cells classically associated with the detection of missing self through loss of their respective MHC ligand. Some KIR specificities for allelic classical class I MHC (MHC-I) have been described, whereas other KIR receptor-ligand relationships, including those associated with nonclassical MHC-I, have yet to be clearly defined. We report in this article that KIR3DL2 and KIR2DS4 and the nonclassical Ag HLA-F, expressed as a free form devoid of peptide, physically and functionally interact. These interactions extend to include classical MHC-I open conformers as ligands, defining new relationships between KIR receptors and MHC-I. The data collectively suggest a broader, previously unrecognized interaction between MHC-I open conformers--including prototypical HLA-F--and KIR receptors, acting in an immunoregulatory capacity centered on the inflammatory response.

Citing Articles

Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy.

Zhu A, Bai Y, Nan Y, Ju D Clin Transl Med. 2024; 14(11):e70046.

PMID: 39472273 PMC: 11521791. DOI: 10.1002/ctm2.70046.

Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection.

Sun W, Gao C, Gladkov G, Roseto I, Carrere L, Parsons E J Exp Med. 2024; 221(11).

PMID: 39466203 PMC: 11519379. DOI: 10.1084/jem.20241091.

The role of circular RNA targeting IGF2BPs in cancer-a potential target for cancer therapy.

Luo X, Shi J, Wang S, Jin X J Mol Med (Berl). 2024; 102(11):1297-1314.

PMID: 39287635 DOI: 10.1007/s00109-024-02488-8.

Diversity in the HLA-I Recognition of HLA-F Monoclonal Antibodies: HLA-F or HLA-Ib Monospecific, HLA-E or HLA-G Bispecific Antibodies with or without HLA-Ia Reactivity.

Ravindranath M, Ravindranath N, Amato-Menker C, Hilali F, Filippone E Antibodies (Basel). 2024; 13(1).

PMID: 38390869 PMC: 10885067. DOI: 10.3390/antib13010008.

Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success.

Rodriguez G, Yakubovich E, Vanderhyden B Cancers (Basel). 2023; 15(23).

PMID: 38067396 PMC: 10705691. DOI: 10.3390/cancers15235694.

References

Cella M, Colonna M . Cloning human natural killer cells. Methods Mol Biol. 2000; 121:1-4. DOI: 10.1385/1-59259-044-6:1. View

Bashirova A, Thomas R, Carrington M . HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol. 2011; 29:295-317. PMC: 3725604. DOI: 10.1146/annurev-immunol-031210-101332. View

Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H . Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol. 2004; 34(6):1673-9. DOI: 10.1002/eji.200425089. View

Lee N, Geraghty D . HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol. 2003; 171(10):5264-71. DOI: 10.4049/jimmunol.171.10.5264. View

Lee N, Ishitani A, Geraghty D . HLA-F is a surface marker on activated lymphocytes. Eur J Immunol. 2010; 40(8):2308-18. PMC: 3867582. DOI: 10.1002/eji.201040348. View

Pyo C, Williams L, Moore Y, Hyodo H, Li S, Zhao L . HLA-E, HLA-F, and HLA-G polymorphism: genomic sequence defines haplotype structure and variation spanning the nonclassical class I genes. Immunogenetics. 2006; 58(4):241-51. DOI: 10.1007/s00251-005-0076-z. View

WAINWRIGHT S, Biro P, Holmes C . HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern. J Immunol. 1999; 164(1):319-28. DOI: 10.4049/jimmunol.164.1.319. View

Arosa F, Santos S, Powis S . Open conformers: the hidden face of MHC-I molecules. Trends Immunol. 2007; 28(3):115-23. DOI: 10.1016/j.it.2007.01.002. View

Erlebacher A . Immunology of the maternal-fetal interface. Annu Rev Immunol. 2013; 31:387-411. DOI: 10.1146/annurev-immunol-032712-100003. View

10.

Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H . Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol. 2003; 171(3):1376-84. DOI: 10.4049/jimmunol.171.3.1376. View

11.

Kulkarni S, Martin M, Carrington M . The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008; 20(6):343-52. PMC: 3501819. DOI: 10.1016/j.smim.2008.06.003. View

12.

Jones D, Kosmoliaptsis V, Apps R, Lapaque N, Smith I, Kono A . HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol. 2011; 186(5):2990-7. DOI: 10.4049/jimmunol.1003078. View

13.

Marcenaro E, Carlomagno S, Pesce S, Moretta A, Sivori S . Bridging innate NK cell functions with adaptive immunity. Adv Exp Med Biol. 2011; 780:45-55. DOI: 10.1007/978-1-4419-5632-3_5. View

14.

Vivian J, Duncan R, Berry R, OConnor G, Reid H, Beddoe T . Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature. 2011; 479(7373):401-5. PMC: 3723390. DOI: 10.1038/nature10517. View

15.

Chrul S, Polakowska E, Szadkowska A, Bodalski J . Influence of interleukin IL-2 and IL-12 + IL-18 on surface expression of immunoglobulin-like receptors KIR2DL1, KIR2DL2, and KIR3DL2 in natural killer cells. Mediators Inflamm. 2006; 2006(4):46957. PMC: 1618942. DOI: 10.1155/MI/2006/46957. View

16.

Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A . Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood. 2008; 112(3):708-10. DOI: 10.1182/blood-2008-02-137521. View

17.

Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina T . Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol. 2005; 78(2):359-71. DOI: 10.1189/jlb.0604360. View

18.

Cooley S, Weisdorf D, Guethlein L, Klein J, Wang T, Le C . Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010; 116(14):2411-9. PMC: 2953880. DOI: 10.1182/blood-2010-05-283051. View

19.

Khakoo S, Geller R, Shin S, Jenkins J, Parham P . The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J Exp Med. 2002; 196(7):911-21. PMC: 2194033. DOI: 10.1084/jem.20020304. View

20.

Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M . HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A. 1998; 95(9):5199-204. PMC: 20238. DOI: 10.1073/pnas.95.9.5199. View